AstraZeneca (NYSE:AZN)‘s stock had its “market perform” rating reaffirmed by investment analysts at Leerink Swann in a research report issued on Thursday. They presently have a $36.00 price objective on the stock, up from their previous price objective of $33.00. Leerink Swann’s price target would indicate a potential upside of 2.65% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. JPMorgan Chase & Co. upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Sanford C. Bernstein upgraded AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $30.00 to $39.00 in a report on Friday, September 22nd. Citigroup upgraded AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. BMO Capital Markets set a $38.00 price objective on AstraZeneca and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average target price of $34.48.

AstraZeneca (NYSE:AZN) traded down $0.01 during mid-day trading on Thursday, hitting $35.07. The company had a trading volume of 3,102,454 shares, compared to its average volume of 3,040,000. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The stock has a market cap of $87,120.00, a P/E ratio of 25.05, a PEG ratio of 3.42 and a beta of 0.76. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 EPS. sell-side analysts expect that AstraZeneca will post 1.88 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Bank & Trust increased its holdings in AstraZeneca by 19.3% during the 4th quarter. First Bank & Trust now owns 55,597 shares of the company’s stock worth $1,929,000 after purchasing an additional 9,004 shares during the period. Bank of Montreal Can increased its holdings in AstraZeneca by 243.4% during the 4th quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after purchasing an additional 294,246 shares during the period. Clean Yield Group purchased a new stake in AstraZeneca during the 4th quarter worth about $205,000. Private Trust Co. NA purchased a new stake in AstraZeneca during the 4th quarter worth about $310,000. Finally, BLB&B Advisors LLC increased its holdings in AstraZeneca by 133.8% during the 4th quarter. BLB&B Advisors LLC now owns 54,849 shares of the company’s stock worth $1,903,000 after purchasing an additional 31,388 shares during the period. Institutional investors own 14.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/18/astrazeneca-azn-receives-market-perform-rating-from-leerink-swann.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.